Aaron Gerds
0000-0002-3422-1309
Cleveland Clinic
15 papers found
Refreshing results…
RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort
Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials
Dasatinib/Prednisone Induction Followed by Blinatumomab/Dasatinib in Ph+ Acute Lymphoblastic Leukemia
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study
A geno-clinical decision model for the diagnosis of myelodysplastic syndromes
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL–negative MPN in blast phase
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase
Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1
The association of histologic grade with acute graft-versus-host disease response and outcomes: NARKHEDE et al.
Missing publications? Search for publications with a matching author name.